SỬ DỤNG THUỐC ỨC CHẾ SGLT2 Ở NGƯỜI SUY TIM NHẬP VIỆN

Abstract

To improve the outcome of heart failure, domestically and internationally current guidelines indicated Sodium-glucose-cortransporter-2 inhibitors (SGLT2i) for heart failure patients with reduced, midly reduced or preserved ejection fraction with or without diabetes. Objective: To survey the incidence and time of using SGLT2i in 3 groups: Reduced, mildly reduced and preserved ejection fraction. To describe the characters of patients on SGLT2i. Subjects and methods: Prospective, descriptive, cross-sectional study on heart failure patients admitted to the Cardiology Department of University of Medicine and Pharmacy Hospital in HCM city from May 2023 to August 2023. Results: Among 118 cases of hospitalization for heart failure 71 (60.2%) patients were using SGLT2i: HFrEF 78.3%, HFmEF 66.7%, HFpEF 41.2% (p<0.001). In term of prescribed day from admission, HFrEF after 2.7±1.8 days, HFmEF after 3.1±1.5 days, and HFpEF after 4.9±3.9 days. Taking SGLT2i on the first day hospitalization of HFrEF, HFmEF and HFpEF was 22.9%, 14.3%, 18.2% respectively (p<0,001). Using all four-pillar drugs was in the HFrEF 41.3%, HFmEF 14.3%, HFpEF 9.8% (p =0.02).  the group using SGLT2i had HFrEF 49.3%, HFmEF 19.7%, HFpEF 31%. Age groups over and under 60 years old, gender, heart rate, hemoglobin, NT-proBNP, and the rate of using ARBi and ARNI drugs were differentiated between the group with and without SGLT2i. Conclusion: SGLT2 inhibitors was prescribed most and earliest in the HFrEF group while least and latest in the HfpEF group. There was a lot of difference between SGLT2 and non-SGLT2 group.